Home LiteratureArticle Details
PMID: 21934683 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma.

British journal of cancer ·Vol. 105 ·No. 8 ·2011-10-11 ·Pages 1191-6

Hotta K, Sho M, Fujimoto K, Shimada K, Yamato I, Anai S, Konishi N, Hirao Y, Nonomura K, Nakajima Y

Abstract

Memory T cells are well known to have a critical role for host defense in humans. However, their role in actual human cancer remains largely unknown. In this study, we tried to reveal the clinical importance of tumour-infiltrating CD45RO+ memory T cells in renal cell carcinoma (RCC). We analysed 105 patients with RCC, who received radical or partial nephrectomy. Those were 65 in TNM stage I, 7 in stage II, 15 in stage III, and 18 in stage IV, respectively. CD45RO expression was evaluated by immunohistochemistry. CD4 and CD8 expressions were also systematically assessed in the same manner. Patients with higher TNM stage or high nuclear grade were found to have higher densities of CD45RO. Furthermore, CD45RO status was positively correlated with preoperative C-reactive protein level. In prognostic analysis, CD45RO+lo patients had a significantly better prognosis than CD45RO+hi patients. There was also a significant difference between CD4+lo and CD4+hi groups, whereas no significant difference was observed in CD8 T-cell status. Finally, multivariate analysis revealed that CD45RO+ status was the independent prognostic factor for patient overall survival. CD45RO+ memory T-cell status has a significant independent prognostic value, indicating that the adaptive immune response is functionally critical in human RCC.

MeSH Terms
Carcinoma, Renal Cell/immunology Humans Immunohistochemistry Immunologic Memory Kidney Neoplasms/immunology Leukocyte Common Antigens/immunology Lymphocytes, Tumor-Infiltrating/immunology Prognosis
Chemicals
Leukocyte Common Antigens
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Hotta K
Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Sho M
Fujimoto K
Shimada K
Yamato I
Anai S
Konishi N
Hirao Y
Nonomura K
Nakajima Y
References (35)
35 references, click to expand
  1. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
    N Engl J Med. 2000 Sep 14;343(11):750-8 PMID: 10984562
  2. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer.
    Br J Cancer. 2008 Nov 18;99(10):1704-11 PMID: 18941457
  3. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes.
    Int J Cancer. 1995 Jun 9;61(6):780-5 PMID: 7790111
  4. Pro-inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal cell carcinoma.
    Eur Urol. 1999 Jan;35(1):70-80 PMID: 9933797
  5. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.
    J Clin Oncol. 1999 Aug;17(8):2530-40 PMID: 10561319
  6. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC).
    Cancer. 1997 Sep 1;80(5):992-3 PMID: 9307205
  7. The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer.
    Br J Cancer. 2006 Mar 27;94(6):781-4 PMID: 16523196
  8. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma.
    Clin Cancer Res. 1999 May;5(5):1219-29 PMID: 10353760
  9. Treatment of metastatic renal cell carcinoma.
    Nat Rev Urol. 2010 Jun;7(6):327-38 PMID: 20458330
  10. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity.
    Cancer Res. 2001 Jul 1;61(13):5132-6 PMID: 11431351
  11. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.
    J Clin Oncol. 2003 Aug 15;21(16):3127-32 PMID: 12915604
  12. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells.
    Clin Cancer Res. 2002 Nov;8(11):3369-76 PMID: 12429623
  13. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
    J Clin Oncol. 2009 Aug 1;27(22):3584-90 PMID: 19487381
  14. Renal-cell carcinoma.
    N Engl J Med. 2005 Dec 8;353(23):2477-90 PMID: 16339096
  15. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
    Science. 2006 Sep 29;313(5795):1960-4 PMID: 17008531
  16. Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma.
    J Immunother. 1997 Nov;20(6):479-87 PMID: 9409454
  17. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.
    Clin Cancer Res. 2007 Mar 15;13(6):1757-61 PMID: 17363529
  18. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma.
    J Thorac Cardiovasc Surg. 2008 Apr;135(4):823-9 PMID: 18374762
  19. Limiting dilution analysis of proliferative responses in human lymphocyte populations defined by the monoclonal antibody UCHL1: implications for differential CD45 expression in T cell memory formation.
    Eur J Immunol. 1988 Nov;18(11):1653-61 PMID: 2974420
  20. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients.
    Cancer. 2007 Sep 15;110(6):1241-7 PMID: 17639589
  21. Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival.
    Cancer. 2006 Jul 1;107(1):46-53 PMID: 16708355
  22. Prognostic significance of morphologic parameters in renal cell carcinoma.
    Am J Surg Pathol. 1982 Oct;6(7):655-63 PMID: 7180965
  23. Effect of tumor-infiltrating lymphocyte subsets on prognosis and susceptibility to interferon therapy in patients with renal cell carcinoma.
    Urol Int. 2002;69(1):51-6 PMID: 12119440
  24. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer.
    Br J Cancer. 2003 Nov 17;89(10):1906-8 PMID: 14612901
  25. The relationships among tumor-infiltrating lymphocytes, histopathologic findings, and long-term clinical follow-up in renal cell carcinoma.
    Mod Pathol. 1992 Jul;5(4):420-5 PMID: 1495948
  26. Effector memory T cells, early metastasis, and survival in colorectal cancer.
    N Engl J Med. 2005 Dec 22;353(25):2654-66 PMID: 16371631
  27. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses.
    Clin Cancer Res. 2004 Jul 15;10(14):4699-708 PMID: 15269142
  28. Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells.
    J Immunol. 1988 Apr 1;140(7):2171-8 PMID: 2965180
  29. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.
    Clin Cancer Res. 2005 Apr 15;11(8):2947-53 PMID: 15837746
  30. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
    Cancer Res. 2008 Apr 15;68(8):2993-3000 PMID: 18413769
  31. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.
    J Clin Oncol. 2009 Dec 10;27(35):5944-51 PMID: 19858404
  32. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
    J Urol. 2005 Jan;173(1):52-5 PMID: 15592024
  33. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
    J Urol. 2008 Aug;180(2):515-9 PMID: 18550105
  34. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
    Eur Urol. 2009 May;55(5):1145-53 PMID: 18930583
  35. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    J Clin Oncol. 2009 Jul 10;27(20):3312-8 PMID: 19451442
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
1532-1827
DOI
10.1038/bjc.2011.368
Published
2011-10-11
Epub
2011-00-20
Pages
1191-6
Language
English
Region
England
NLM ID
0370635
PMCID
PMC3208496
Subset
IM
External Links
PubMed source DOI: 10.1038/bjc.2011.368 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2